[ad_1]
CB Scientific, Inc. has launched the MyCardia AT, a next-generation cardiac event monitor designed to enhance remote cardiac monitoring for patients with intermittent heart rhythm issues.
Through MyCardia AT, CB Scientific aims to improve early detection of cardiac arrhythmias, which can reduce the risk of stroke, heart damage, and death. The cardiac event monitor also serves as an in-office ECG screening tool. The lightweight, user-friendly device is FDA-cleared and compatible with iOS and Android smartphones. This functionality allows patients to transmit event recordings via the MyCardia app and effectively streamlines data management and communication.
The company plans to distribute the MyCardia AT through its established network in Southeast Asia, Hong Kong, and Macau, with regulatory submissions underway for markets in China and Canada.
Image Credit: CB Scientific
[ad_2]
Source link
